PL4058060T3 - Hamowanie interferonu typu i w toczniu rumieniowatym układowym - Google Patents
Hamowanie interferonu typu i w toczniu rumieniowatym układowymInfo
- Publication number
- PL4058060T3 PL4058060T3 PL20804531.0T PL20804531T PL4058060T3 PL 4058060 T3 PL4058060 T3 PL 4058060T3 PL 20804531 T PL20804531 T PL 20804531T PL 4058060 T3 PL4058060 T3 PL 4058060T3
- Authority
- PL
- Poland
- Prior art keywords
- type
- lupus erythematosus
- systemic lupus
- interferon inhibition
- interferon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933672P | 2019-11-11 | 2019-11-11 | |
| US202063031848P | 2020-05-29 | 2020-05-29 | |
| US202063089345P | 2020-10-08 | 2020-10-08 | |
| PCT/EP2020/081770 WO2021094378A1 (en) | 2019-11-11 | 2020-11-11 | Type i interferon inhibition in systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4058060T3 true PL4058060T3 (pl) | 2025-07-28 |
Family
ID=73344065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20804531.0T PL4058060T3 (pl) | 2019-11-11 | 2020-11-11 | Hamowanie interferonu typu i w toczniu rumieniowatym układowym |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220396630A1 (pl) |
| EP (2) | EP4058060B1 (pl) |
| JP (1) | JP2023501462A (pl) |
| KR (1) | KR102766960B1 (pl) |
| CN (1) | CN114728059A (pl) |
| AU (1) | AU2020382850B2 (pl) |
| CA (1) | CA3159568A1 (pl) |
| DK (1) | DK4058060T3 (pl) |
| ES (1) | ES3021878T3 (pl) |
| FI (1) | FI4058060T3 (pl) |
| HU (1) | HUE070947T2 (pl) |
| IL (1) | IL292706A (pl) |
| PL (1) | PL4058060T3 (pl) |
| PT (1) | PT4058060T (pl) |
| TW (1) | TW202133877A (pl) |
| WO (1) | WO2021094378A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237647A (zh) * | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| US20240327529A1 (en) * | 2020-11-18 | 2024-10-03 | Astrazeneca Ab | Steroid sparing |
| LT4114465T (lt) | 2021-04-23 | 2023-11-10 | Astrazeneca Ab | Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai |
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| EP4545090A1 (en) * | 2023-10-27 | 2025-04-30 | Universität Leipzig | Interferon-a receptor immune modulator for use as a medicament |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781705B1 (en) | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| HUE028958T2 (en) | 2008-02-08 | 2017-01-30 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| ES2613055T3 (es) | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| KR20210131354A (ko) * | 2019-02-15 | 2021-11-02 | 아스트라제네카 아베 | I형 인터페론-매개 장애 |
-
2020
- 2020-11-11 KR KR1020227018548A patent/KR102766960B1/ko active Active
- 2020-11-11 US US17/755,801 patent/US20220396630A1/en active Pending
- 2020-11-11 EP EP20804531.0A patent/EP4058060B1/en active Active
- 2020-11-11 DK DK20804531.0T patent/DK4058060T3/da active
- 2020-11-11 PT PT208045310T patent/PT4058060T/pt unknown
- 2020-11-11 IL IL292706A patent/IL292706A/en unknown
- 2020-11-11 ES ES20804531T patent/ES3021878T3/es active Active
- 2020-11-11 JP JP2022526517A patent/JP2023501462A/ja active Pending
- 2020-11-11 CA CA3159568A patent/CA3159568A1/en active Pending
- 2020-11-11 EP EP24205849.3A patent/EP4494712A3/en active Pending
- 2020-11-11 HU HUE20804531A patent/HUE070947T2/hu unknown
- 2020-11-11 CN CN202080077901.4A patent/CN114728059A/zh active Pending
- 2020-11-11 AU AU2020382850A patent/AU2020382850B2/en active Active
- 2020-11-11 TW TW109139396A patent/TW202133877A/zh unknown
- 2020-11-11 WO PCT/EP2020/081770 patent/WO2021094378A1/en not_active Ceased
- 2020-11-11 PL PL20804531.0T patent/PL4058060T3/pl unknown
- 2020-11-11 FI FIEP20804531.0T patent/FI4058060T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4058060A1 (en) | 2022-09-21 |
| US20220396630A1 (en) | 2022-12-15 |
| AU2020382850B2 (en) | 2025-01-16 |
| FI4058060T3 (fi) | 2025-03-21 |
| KR20220099985A (ko) | 2022-07-14 |
| EP4058060B1 (en) | 2025-02-19 |
| PT4058060T (pt) | 2025-04-24 |
| WO2021094378A1 (en) | 2021-05-20 |
| CA3159568A1 (en) | 2021-05-20 |
| AU2020382850A1 (en) | 2022-06-23 |
| KR102766960B1 (ko) | 2025-02-11 |
| JP2023501462A (ja) | 2023-01-18 |
| EP4494712A2 (en) | 2025-01-22 |
| CN114728059A (zh) | 2022-07-08 |
| EP4494712A3 (en) | 2025-03-26 |
| IL292706A (en) | 2022-07-01 |
| ES3021878T3 (en) | 2025-05-27 |
| DK4058060T3 (da) | 2025-03-17 |
| TW202133877A (zh) | 2021-09-16 |
| HUE070947T2 (hu) | 2025-07-28 |
| WO2021094378A9 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4058060T3 (pl) | Hamowanie interferonu typu i w toczniu rumieniowatym układowym | |
| SG11202100071YA (en) | Fusosome compositions and uses thereof | |
| CA187856S (en) | Caddy | |
| SG11202011015QA (en) | Fusosome compositions and uses thereof | |
| PL3831977T3 (pl) | Blacha cienka ze stali elektrotechnicznej o ziarnach zorientowanych | |
| IL279755A (en) | Senolytic preparations and their uses | |
| GB202117980D0 (en) | Relithiation in oxidizing conditions | |
| CA187509S (en) | Charger | |
| GB2584694B (en) | Preventing surge | |
| GB201813016D0 (en) | Disconnect sub | |
| PL3744870T3 (pl) | Blacha cienka ze stali elektrotechnicznej o ziarnach zorientowanych | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| IL277663A (en) | Arunumab preparations and their uses | |
| ZA202105075B (en) | Antiviral compositions and methods | |
| ZA202005144B (en) | Parenteral formulations and uses thereof | |
| GB201812334D0 (en) | Compositions and uses thereof | |
| GB201807576D0 (en) | Compositions and uses thereof | |
| GB2570354B (en) | Postcard | |
| GB201821138D0 (en) | Compositions and uses thereof | |
| GB201811809D0 (en) | Charger | |
| GB201903208D0 (en) | Dancing in the moonlight | |
| CA184772S (en) | Charger | |
| GB201904546D0 (en) | Component with insert | |
| GB201811331D0 (en) | Improvements in pallets | |
| AU2018903948A0 (en) | Surfboard Protector |